1. Home
  2. ACCL vs LPCN Comparison

ACCL vs LPCN Comparison

Compare ACCL & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACCL

Acco Group Holdings Limited Ordinary Shares

HOLD

Current Price

$1.78

Market Cap

20.2M

ML Signal

HOLD

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$2.44

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACCL
LPCN
Founded
2009
1997
Country
Hong Kong
United States
Employees
22
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.2M
19.1M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
ACCL
LPCN
Price
$1.78
$2.44
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
26.1K
66.6K
Earning Date
05-20-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
N/A
$1,976,677.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$92.00
P/E Ratio
$17.13
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.23
$1.81
52 Week High
$5.00
$12.37

Technical Indicators

Market Signals
Indicator
ACCL
LPCN
Relative Strength Index (RSI) 63.17 50.88
Support Level $1.30 $2.16
Resistance Level $1.82 $2.46
Average True Range (ATR) 0.07 0.16
MACD 0.00 0.01
Stochastic Oscillator 100.00 44.30

Price Performance

Historical Comparison
ACCL
LPCN

About ACCL Acco Group Holdings Limited Ordinary Shares

Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: